Document Detail


Interactions between warfarin and three commonly prescribed fluoroquinolones.
MedLine Citation:
PMID:  18413687     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To critically evaluate a possible increased anticoagulant response during concomitant warfarin and fluoroquinolone therapy. DATA SOURCES: A literature search was conducted using PubMed, International Pharmaceutical Abstracts, and MEDLINE, from inception to January 2008, combining the term warfarin individually with ciprofloxacin, levofloxacin, and moxifloxacin. These 3 quinolones were selected based on their commercial availability and use in the US. STUDY SELECTION AND DATA EXTRACTION: All publication types including human participants and published in English were eligible for review. Reports were selected based on the use of typical treatment courses of fluoroquinolones during concomitant warfarin therapy and the reporting of prothrombin time (PT) or international normalized ratio (INR). DATA SYNTHESIS: Twenty-two publications were evaluated including 16 case reports or case series, 2 retrospective cohort studies, and 4 prospective studies, which included 2 placebo-controlled investigations. Identified reports covered a wide range of patient ages with multiple comorbidities. Changes in PT and INR values were considerably variable and inconsistent during concomitant warfarin and fluoroquinolone therapy. Results from the 6 structured reports demonstrated mean increases in PT and INR values that were clinically insignificant. However, some patients experienced significant increases above the desired therapeutic range. Increased anticoagulation was typically observed within the first week of concomitant fluoroquinolone therapy. Bleeding complications during times of increased anticoagulation were not always observed, but did result in death for 2 patients. CONCLUSIONS: Published data show no consistent increase in anticoagulant effects during concomitant warfarin and 3 commonly prescribed fluoroquinolones. Therefore, more frequent monitoring during concomitant therapy would be prudent.
Authors:
Douglas N Carroll; Dana G Carroll
Related Documents :
1433657 - Current use of inferior vena cava filters.
15289387 - Comparing warfarin with aspirin after biological aortic valve replacement: a prospectiv...
20027657 - Impact of chronic antithrombotic therapy on hospital course of patients with acute myoc...
15099277 - Increased levels of soluble tissue factor during long-term treatment with warfarin in p...
10810487 - The biologic response to laser thermal modification in an in vivo sheep model.
16190847 - Hemiresection of the prostate: short-term randomized comparison with standard transuret...
Publication Detail:
Type:  Journal Article; Review     Date:  2008-04-15
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  42     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-22     Completed Date:  2008-06-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  680-5     Citation Subset:  IM    
Affiliation:
Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Tuscaloosa, AL 35487, USA. carrodn@auburn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aza Compounds / adverse effects,  metabolism*
Ciprofloxacin / adverse effects,  metabolism*
Drug Interactions / physiology
Drug Monitoring / methods
Drug Therapy, Combination
Humans
International Normalized Ratio / methods
Ofloxacin / adverse effects,  metabolism*
Quinolines / adverse effects,  metabolism*
Warfarin / adverse effects,  metabolism*
Chemical
Reg. No./Substance:
0/Aza Compounds; 0/Quinolines; 0/moxifloxacin; 81-81-2/Warfarin; 82419-36-1/Ofloxacin; 85721-33-1/Ciprofloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Corticosteroids for prevention of postextubation laryngeal edema in adults.
Next Document:  Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program.